Status:
COMPLETED
Mechanisms of Dyspnea Relief During Exercise in COPD Patients Following Treatment With Tiotropium (Spiriva)
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
40-75 years
Phase:
PHASE3
Brief Summary
To explore the mechanisms of dyspnea relief during exercise in patients with COPD following treatment with tiotropium bromide (Spiriva)
Detailed Description
This was a single-centre, randomised, double-blind, placebo-controlled, cross-over study. The duration of subject participation was 9 weeks. There was an initial screening period of up to 2 weeks. The...
Eligibility Criteria
Inclusion
- Inclusion criteria: Patients with chronic obstructive pulmonary disease (COPD) with FEV1 \< 70% predicted and FRC \> 120% predicted, a cigarette smoking history \> 20 pack-years, and moderate to severe chronic dyspnea
- Exclusion criteria: patients with a history of asthma, allergic rhinitis or atopy; patients who participated in a rehabilitation program for COPD within 6 weeks prior to screening
Exclusion
Key Trial Info
Start Date :
January 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2003
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT00274027
Start Date
January 1 2001
End Date
March 1 2003
Last Update
November 1 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kingston General Hospital
Kingston, Ontario, Canada, K7L 2V6